• Users Online: 464
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login

  About Us

  About the Societies

Saudi Society of Hematology (http://hematology-sa.org/)

The society was established to be an official league for physicians, scientists, technologists, patients and everyone with interest in hematology and transfusion medicine in the Kingdom of Saudi Arabia in particular and in the Middle East, in general. Its primary focus is to promote medical research in hematology and to provide a platform for the hematologists, practitioner researchers and scientists to discuss and disseminate their experience with the medical community and the general public. In this regard, the society is active in providing support and infrastructure to those interested in conducting research in the field of benign, malignant and pre-malignant hematological disorders, and transfusion medicine. The society hosts conferences in the Kingdom of Saudi Arabia annually, which attracts significant number of hematologists, general practitioners, researchers and scientists from all over the Arab and GCC Countries to discuss the latest breakthroughs in blood disorders.

Saudi Society of Blood Disorders

With its focus on Malignant Hematological Disorders and Thrombosis, Saudi Society of Blood Disorders serves the medical community of Hemato-Oncologists in the region by providing a forum to discuss and disseminate cutting edge technology and treatment options available in this field of medicine. The Society aims to actively pursue latest research in novel therapies like Stem Cell Transplantation, Immune- and Gene-Therapy, and support and fund the researchers in the Kingdom of Saudi Arabia.
  About the Journal

Journal of Applied Hematology, an official publication of Saudi Scientific Society of Hematology and Saudi Society of Blood Disorders, is a peer-reviewed on-line journal, published quarterly with print on demand compilation of issues. The journal is one of the few journals in the Middle East with focus on issues relating to hematological disorders and their treatment in the region. The journal's policy is to promote clinical, applied, translational and bio-medical research in the field of benign, pre-malignant and malignant hematological disorders. This is being served with a large group of local and international reviewers providing critical evaluation as well as advice for young investigators and aspiring authors. Journal’s full text is available online at www.jahjournal.org. The journal allows free access (Open Access) to its contents and permits authors to self-archive final accepted version of the articles on any OAI-compliant institutional / subject-based repository. The journal does not charge for submission, processing or publication of manuscripts, or reproduction of photographs.

Abstracting and Indexing Information

The journal is registered with the following abstracting partners:
Baidu Scholar, CNKI (China National Knowledge Infrastructure), EBSCO Publishing's Electronic Databases, Ex Libris Primo Central, Google Scholar, Hinari, Infotrieve, National Science Library, ProQuest, TdNet, Wanfang Data

The journal is indexed with, or included in, the following:
DOAJ, Index Copernicus

Journal Ethics

Wolters Kluwer and Journal/Association are committed to meeting and upholding standards of ethical behavior at all stages of the publication process. We follow closely the industry associations, such as the Committee on Publication Ethics (COPE), International Committee of Medical Journal Editors (ICMJE) and World Association of Medical Editors (WAME), that set standards and provide guidelines for best practices in order to meet these requirements. For a summary of our specific policies regarding duplicate publication, conflicts of interest, patient consent, etc., please visit www.Medknow.com/EthicalGuidelines.asp

Open Access Publication and Creative Commons Licensing

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

Digital Archiving

Wolters Kluwer Medknow provides for long-term digital preservation through two primary partnerships, Portico and CLOCKSS.

Portico is a leading digital preservation service worldwide. The content is preserved as an archival version and is not publically accessible via Portico, but is provided when required under specific conditions, such as discontinuation of the collection or catastrophic failure of the website.

CLOCKSS will enable any library to maintain their own archive of content from Wolters Kluwer Medknow and other publishers, with minimal technical effort and using cheaply available hardware.

Ahead of Print policy

Articles published online under the Ahead of Print model are considered published and can be cited and quoted using the DOI as the reference source. Wolters Kluwer Medknow has a policy that changes will not be made after publication of an article without following accepted procedures for making corrections to the scientific record.

Advertisements

While advertisements are crucial to this journal to be able to keep all content free for everyone, ethical considerations are in place to ensure the integrity of the journal and its content:

  • "Pop-up" and "banner" ads appear on a random, rotating basis. The advertiser has no control or input over the pages where their ads appear.
  • The Editorial Board has full and final approval over the content of all advertisements.
  • Advertisers will never be shown any manuscripts or other content prior to publication.

  Scope of the journal

The journal will cover technical and clinical studies related to health, ethical and social issues in field of Thrombosis, bleeding disorders, Hemoglobinopathies, transfusion medicine, hematological malignancies and stem cell transplantation. Articles with clinical interest and implications will be given preference.

    Medknow Publications   Top
Feedback
Subscribe
Editorial board
Subscribe this journal
Submit articles
Most popular articles
Joiu us as a reviewer
Email alerts
Recommend this journal